Stockscreener 앱 받기
1.64
7.34%
-0.13
전일 마감가:
$1.77
열려 있는:
$1.78
하루 거래량:
487.77K
Relative Volume:
1.81
시가총액:
$37.55M
수익:
$950.10K
순이익/손실:
$-16.69M
주가수익비율:
-1.9759
EPS:
-0.83
순현금흐름:
$-15.16M
1주 성능:
+3.14%
1개월 성능:
+37.82%
6개월 성능:
+57.69%
1년 성능:
+20.59%
1일 변동 폭
$1.63
$1.80
1주일 범위
$1.475
$1.80
52주 변동 폭
$0.86
$2.40
Femasys Inc Stock (FEMY) Company Profile
명칭
Femasys Inc
전화
770-500-3910
주소
3950 JOHNS CREEK COURT, SUWANEE
FEMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
1.64 | 37.55M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
591.79 | 211.07B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.43 | 65.30B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
90.31 | 44.67B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
231.69 | 34.04B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
88.48 | 17.62B | 3.90B | 392.30M | 288.10M | 1.95 |
Femasys Inc 주식(FEMY)의 최신 뉴스
Is Femasys (NASDAQ:FEMY) Using Debt In A Risky Way? - Simply Wall St
Femasys gains UK approval for women's health products - MSN
FY2024 Earnings Estimate for Femasys Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for Femasys Q1 Earnings? - Defense World
Femasys gains UK approval for women’s health products By Investing.com - Investing.com Nigeria
Femasys Announces UK Regulatory Approvals for FemaSeed® for - GlobeNewswire
Femasys (NASDAQ:FEMY) Given “Buy” Rating at HC Wainwright - Defense World
Femasys gains UK approval for women's health products By Investing.com - Investing.com Australia
Major Win for Infertility Treatment: Femasys (FEMY) Unlocks UK Market with Triple Product Approval - StockTitan
Head-To-Head Survey: Sonoma Pharmaceuticals (NASDAQ:SNOA) vs. Femasys (NASDAQ:FEMY) - Defense World
Femasys gains approvals for infertility and diagnostic products in Israel - MSN
Pap Test Market: Current Analysis and Forecast (2022-2028) - UnivDatos Market Insights
Femasys Announces Israeli Regulatory Approvals for - GlobeNewswire
Major Win for Women's Health: Femasys Triple-Product Approval Opens New Market - StockTitan
Femasys announces notices of intention to grant for two new European patent applications - MSN
Femasys Announces Notices of Intention to Grant for Two New - GlobeNewswire
Game-Changing Birth Control Tech: Femasys Locks Down Crucial EU Patents for Non-Surgical Alternative - StockTitan
Femasys gets notice of allowance for new U.S. patent application covering use of Femaseed - MSN
Femasys Inc. Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment - Marketscreener.com
Femasys Announces Notice of Allowance for New U.S. Patent - GlobeNewswire
Femasys Secures Patent Protection for FemaSeed Fertility Treatment Through 2044 - StockTitan
Femasys Inc. (NASDAQ:FEMY) Stock Position Raised by Geode Capital Management LLC - Defense World
Femasys (NASDAQ:FEMY) Stock Price Down 2.8% – What’s Next? - Defense World
HPV Testing & Pap Test Market 2025-2032: Scope, Trend, Expansion Strategies with SWOT Analysis - WICZ
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright - Defense World
Femasys shares hold price target with buy rating on HRC Fertility deal - Investing.com Nigeria
Intratubal Insemination Device Shown Effective, Safe - Streetwise Reports
Femasys Announces Partnership with HRC Fertility, Esteemed - GlobeNewswire
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
The Latest Analyst Ratings For Femasys - Benzinga
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Yahoo Canada Finance
Femasys' FemaSeed Trial Shows Double Pregnancy Success vs Traditional IUI Treatment - StockTitan
Femasys price target lowered to $8 from $10 at Chardan - MSN
Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy
Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian
Femasys Sales Surge 127% as Boston IVF Partnership, FDA Clearance Fuel Growth | FEMY Stock News - StockTitan
Femasys to Exhibit at the Annual AAGL 2024 Global Conference - GlobeNewswire
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys Partners with Boston IVF to Expand Access to Novel Fertility Treatment - Femtech Insider
Femasys secures new patent for FemBloc birth control By Investing.com - Investing.com South Africa
Femasys issued U.S. patent covering FemBloc device - MSN
Femasys Issued New U.S. Patent for FemBloc Permanent Birth Control - MPO-mag
Femasys Inc (FEMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.09%
0.26%
자본화:
|
볼륨(24시간):